These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28192114)

  • 1. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
    El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Peters E; Haughey M; Bienfang D; Jones AM; Julien-Williams P; Cui Y; Villalba JA; Bagwe S; Maurer R; Rosas IO; Moss J; Henske EP
    Chest; 2017 Jun; 151(6):1302-1310. PubMed ID: 28192114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.
    Lamattina AM; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Cui Y; Rosas IO; Moss J; Henske EP; El-Chemaly S
    Chest; 2018 Nov; 154(5):1070-1082. PubMed ID: 30144422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
    Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
    Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.
    Gupta N; Zhang B; Zhou Y; McCormack FX; Ingledue R; Robbins N; Kopras EJ; McMahan S; Singla A; Swigris J; Cole AG; Holz MK
    Chest; 2023 May; 163(5):1144-1155. PubMed ID: 36642366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
    Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
    Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
    Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
    McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
    N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
    Wang Q; Luo M; Xiang B; Chen S; Ji Y
    Respir Res; 2020 Feb; 21(1):55. PubMed ID: 32059669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.
    Krymskaya VP; Courtwright AM; Fleck V; Dorgan D; Kotloff R; McCormack FX; Kreider M
    Respir Med; 2020 Mar; 163():105898. PubMed ID: 32125970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
    Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX;
    Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.
    Seyama K; Kumasaka T; Souma S; Sato T; Kurihara M; Mitani K; Tominaga S; Fukuchi Y
    Lymphat Res Biol; 2006; 4(3):143-52. PubMed ID: 17034294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.
    Takada T; Mikami A; Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Akasaka K; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Sugimoto C; Arai T; Hattori N; Watanabe K; Tamada T; Yoshizawa H; Akazawa K; Tanaka T; Yagi K; Young LR; McCormack FX; Nakata K
    Ann Am Thorac Soc; 2016 Nov; 13(11):1912-1922. PubMed ID: 27513278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis.
    Yoon HY; Hwang JJ; Kim DS; Song JW
    Orphanet J Rare Dis; 2018 Nov; 13(1):204. PubMed ID: 30428897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.
    Zhan Y; Shen L; Xu W; Wu X; Zhang W; Wang J; Li X; Yang Y; Tian X; Xu KF
    Orphanet J Rare Dis; 2018 Feb; 13(1):34. PubMed ID: 29458386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
    Neurohr C; Hoffmann AL; Huppmann P; Herrera VA; Ihle F; Leuschner S; von Wulffen W; Meis T; Baezner C; Leuchte H; Baumgartner R; Zimmermann G; Behr J
    Respir Res; 2011 May; 12(1):66. PubMed ID: 21600034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
    Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
    Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
    N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
    Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
    Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COPD assessment test as a possible tool for evaluating health-related quality of life in lymphangioleiomyomatosis.
    Kato M; Kanehiro Y; Yoshimi K; Kodama Y; Sekiya M; Sato T; Takahashi K; Seyama K;
    Respir Investig; 2018 Nov; 56(6):480-488. PubMed ID: 30143460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.